Heron Therapeutics Inc. reported improved financial results in its second quarter of 2024, with $36 million in net product sales and $25.5 million in gross profit. The company’s CEO, Craig Collard, highlighted milestones and ongoing commercial success, emphasizing revenue growth, margin improvement, and expense reduction. Heron Therapeutics is expanding its partnership with CrossLink and progressing regulatory activities for a fourth quarter launch of the Zynrelef vial access needle. The company has a Prescription Drug User Fee Act goal date of Sept. 23 for Zynrelef VAN.
Source link
Heron Therapeutics announces second-quarter financial results
